ARTICLE | Clinical News
Tyzeka telbivudine: Additional Phase III data
December 24, 2007 8:00 AM UTC
Previously reported 1-year data from the Phase III GLOBE study were published in The New England Journal of Medicine and showed that 600 mg/day of oral telbivudine was non-inferior to 100 mg/day of la...